Serum Amphiregulin expression in severe asthma patients treated with anti-IL-5 therapy
D. Bagnasco (GENOVA (GE), Italy), A. Riccio (GENOVA (GE), Italy), L. De Ferrari (GENOVA (GE), Italy), A. Massolo (Pisa, Italy), M. Caminati (Verona, Italy), A. Manfredi (GENOVA, Italy), G. Senna (Verona, Italy), G. Passalacqua (GENOVA, Italy)
Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Bagnasco (GENOVA (GE), Italy), A. Riccio (GENOVA (GE), Italy), L. De Ferrari (GENOVA (GE), Italy), A. Massolo (Pisa, Italy), M. Caminati (Verona, Italy), A. Manfredi (GENOVA, Italy), G. Senna (Verona, Italy), G. Passalacqua (GENOVA, Italy). Serum Amphiregulin expression in severe asthma patients treated with anti-IL-5 therapy. 2262
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Serum YKL-40 modulation in severe asthma patients treated with Mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020
Monitoring free serum IgE in severe asthma patients treated with omalizumab Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011
Increase in systemic IL-5 is associated with mepolizumab treatment failure in patients with severe asthma Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018
Evolution of patients with severe asthma treated with mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020
Serum levels of IL-6 in adult patients with moderate to severe asthma. Source: International Congress 2017 – Novel mechanisms in asthma Year: 2017
Monitoring free serum IgE in asthma patients treated with omalizumab Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010
Serum eosinophil cationic protein as a potential biomarker for interleukin-5 antibody treatment in patients with severe uncontrolled eosinophilic asthma Source: International Congress 2018 – Biomarkers for evaluating asthma Year: 2018
Omalizumab, a recombinant humanized monoclonal anti-IgE antibody, decreases the risk of serious asthma exacerbations requiring hospitalization in patients with moderate-to-severe allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001
Effect of systemic steroid treatment on serum leptin levels in patients with COPD exacerbation Source: Eur Respir J 2005; 26: Suppl. 49, 284s Year: 2005
Expression of interleukin-4 receptor in bronchial asthma patients treated with specific immunotherapy (SIT) Source: Eur Respir J 2002; 20: Suppl. 38, 589s Year: 2002
Serum Interleukin (IL)-6 levels in patients with severe asthma disease is associated with blood eosinophilia Source: Virtual Congress 2020 – Clinical characteristics and diagnostic tools for phenotyping asthma and COPD Year: 2020
Serum level of soluble interleukin-2 receptors (sIL-2R) during acute asthma exacerbation, and its relation to severity and response to bronchodilator therapy Source: Eur Respir J 2002; 20: Suppl. 38, 141s Year: 2002
Oral corticosteroid treatment reduces serum chitotriosidase activity in patients with COPD Source: Annual Congress 2010 - COPD: treatment and monitoring Year: 2010
Effect of anti-IL-17 biologics on KL-6 level and coexisting interstitial pneumoniain patients with psoriasis Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020
Evaluation of bronchial hyperreactivity and other functional parameters in severe asthma patients treated with anti-interleukin-5 monoclonal antibody (IL5) Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019
Salmeterol treatment improves corticosteroid responsivness in patients with corticosteroid-insensitive severe asthma Source: Annual Congress 2005 - Improving asthma control in the harder-to-reach population Year: 2005
Serum TNF-a, IL-12 and IL-13 levels in severe bronchial asthma patients Source: Eur Respir J 2004; 24: Suppl. 48, 353s Year: 2004
Serum leptin levels in asthmatic children treated with inhaled corticosteroid Source: Eur Respir J 2004; 24: Suppl. 48, 580s Year: 2004
Change of lung function in severe eosinophilic asthma undergoing treatment with anti-interleukin-5 monoclonal antibody Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018
Free serum IL-18 levels and responsiveness to omalizumab in patients with severe asthma Source: International Congress 2016 – Asthma: mechanisms and biomarkers that promote clinical understanding Year: 2016